Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cell infusion shows promise for heart attack recovery

NCT ID NCT00877903

Disease control Sponsor: Mesoblast, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a single intravenous infusion of stem cells (PROCHYMAL) in 220 adults who had their first heart attack within the prior week. The goal was to see if the treatment could safely improve heart function, as measured by MRI scans at 3 months. Participants were randomly assigned to receive either the stem cells or a placebo, and the study is now complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

220 people

The number who actually took part.

Started

Mar 2009

Finished

Mar 2016

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female between 21 and 85 years old, inclusive * First heart attack within 7 days prior to randomization and drug infusion * Baseline left ventricular ejection fraction (LVEF) 20-45% * Hemodynamically stable within 24 hours prior to randomization * Adequate pulmonary function Exclusion Criteria: * Previous medical history of heart attack, heart failure, significant valvular heart disease, aortic dissection * Pacemaker or other device * Pregnant, breast-feeding, or intends to become pregnant during the study * Allergy to cow or pig derived products * Evidence of active malignancy or prior history of active malignancy * Major surgical procedure or major trauma within the past 14 days * Autoimmune disease (e.g., Lupus, Multiple Sclerosis) * Any medical condition, which in the opinion of the Investigator, renders participation unsuitable * Undergone pharmacologic cardioversion or external defibrillation within 24 hours of randomization. * Experienced cardiac arrest more than 36 hours after presentation to site or within 24 hours of randomization.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction

Contacts and locations

Locations

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania, 15212, United States

  • Austin Heart P.A.

    Austin, Texas, 78756, United States

  • Baystate Medical Center

    Springfield, Massachusetts, 01199, United States

  • Cotton-O'Neil Clinical Research Center

    Topeka, Kansas, 66604, United States

  • Drexel University College of Medicine

    Philadelphia, Pennsylvania, 19102, United States

  • Fletcher Allen Health Care

    Burlington, Vermont, 05401, United States

  • McGill University Health Centre

    Montreal, Quebec, H3A 1A1, Canada

  • Mercy Gilbert Medical Center / Catholic Health Care West

    Gilbert, Arizona, 85297, United States

  • Michigan Cardiovascular Institute

    Saginaw, Michigan, 48601, United States

  • Minneapolis Heart Institute

    Minneapolis, Minnesota, 55407, United States

  • Mount Sinai Medical Center

    Miami Beach, Florida, 33140, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Penn State University - Milton S. Hershey Medical Center

    Hershey, Pennsylvania, 17033, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • Stony Brook University Medical Center

    Stony Brook, New York, 11794, United States

  • The Care Group

    Indianapolis, Indiana, 46290, United States

  • The Lindner Research Center

    Cincinnati, Ohio, 45219, United States

  • The Ohio State University Medical Center

    Columbus, Ohio, 43210, United States

  • The Stern Cardiovascular Center

    Germantown, Tennessee, 38138, United States

  • Tufts Medical Center

    Boston, Massachusetts, 02111, United States

  • UC Davis Medical Center

    Sacramento, California, 95817, United States

  • UMDNJ - Robert Wood Johnson Medical School

    New Brunswick, New Jersey, 08903, United States

  • UMass Memorial Medical Center

    Worcester, Massachusetts, 01655, United States

  • University at Buffalo - Buffalo General Hospital

    Buffalo, New York, 14203, United States

  • University of Arizona

    Tucson, Arizona, 85724, United States

  • University of California - San Diego (UCSD)

    San Diego, California, 92103, United States

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, 52242, United States

  • University of Maryland Hospital

    Baltimore, Maryland, 21201, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Texas Health Science Center

    Houston, Texas, 77030, United States

  • University of Wisconsin School of Medicine

    Madison, Wisconsin, 53792, United States

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina, 27157, United States

  • William Beaumont Hospital

    Royal Oak, Michigan, 48073, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.